动物实验,2型糖尿病 z-bio 2021-11-06 320

　　Objective: To explore the effectiveness and feasibility of vaccine immune intervention with human-derived RBP-4 as the target of insulin resistance, and to provide basic research data for the further development of new therapies for type 2 diabetes.

　　Method: Use T7 phage as a vector to express human RBP-4 vaccine and subcutaneously immunize type 2 diabetic mice. At the same time, set up a blank vector group and a blank control group. After two immunizations, the humoral immunity level was measured at different times. Fasting blood glucose and body weight, and the animals were sacrificed at 20 weeks for pathological examination. Results: The RBP-4 vaccine effectively induced the production of anti-RBP-4 IgG antibodies, which peaked at 12 weeks. At the same time, the fasting blood glucose level of the immunized group gradually decreased from the 8th week, and the carriers emptied at the 12th week. There is a significant difference between the blank group and the blank group, and the difference has always remained below the incidence of type 2 diabetes (7 mmol/L). During the experiment, the type 2 diabetic mice in the immunized and empty carrier groups showed no obvious abnormalities, such as curly, upright hair, abrasions or cramps on the nose, and the mouse's heart, liver, spleen, and lungs unit. No obvious pathological changes were observed in the kidney tissue, indicating that the RBP-4 vaccine is safe.

　　 Conclusion: RBP-4 vaccine can significantly reduce the blood sugar level of type 2 diabetic mice, which may be a new breakthrough in the treatment of insulin resistance.